BIO-Europe 2026 has ended. This guide stays up as the record of who was there. See upcoming conferences
Therapeutic insights at BIO‑Europe 2026
Nov 9–11, 2026 Cologne, Germany ~5.8k attendees Website
58 organizations at BIO-Europe 2026 present work in therapeutic insights: 34 drug developers, 15 investors, 5 service providers and 4 academic, government and non-profit bodies. Between them they bring 92 presentations to the program. Most represented: Merck KGaA (11 on the program), Boehringer Ingelheim (5 on the program), Informa (4 on the program). As of Nov 10, 2026.
Format
Top represented
Showing 1–10 of 58 organizations
| Organization | BIO-Europe 2026 Attendance |
|---|---|
Merck KGaA Darmstadt, Germany | ◆Platinum Sponsor |
Science and technology company active in healthcare, life science and electronics; operates as EMD Serono and MilliporeSigma in North America. | Talk Mon Nov 9 09:00–10:00 Building Your BD Career: What Really Moves the Needle What it takes to build a career in drug licensing and partnership deals, from scientific and financial skills to credibility and contacts. Talk Mon Nov 9 15:00–16:15 Merck's EMEA Advance Biotech Grant Program Five young biotech companies pitch their science to Merck, competing for a grant that helps them bring a product to market. Panel Mon Nov 9 13:00–13:45 Open Innovation in Action: How Pharma Is Rewiring the Drug Discovery Ecosystem How big drug companies share their collections of test molecules and data with outside scientists to speed up early drug discovery. Panel Tue Nov 10 14:00–14:45 Immunology under the microscope: New frontiers What is new in drugs for autoimmune and inflammatory diseases: emerging targets, recent trial results, and where companies are investing and partnering. Talk Tue Nov 10 09:15–09:30 Pharma Presentation: Merck Merck's three businesses: medicines for diseases such as multiple sclerosis and cancer, tools for scientists, and technology for electronics. Panel Tue Nov 10 16:00–16:45 Unlocking Clinical Trial Systems How EU clinical trial rules and a planned EU biotech law affect trial approval times, and whether Europe can speed up safely. Panel Wed Nov 11 09:00–09:45 From NAMs (New Approach Methodologies) Innovation to Regulatory acceptance: Accelerating human-relevant modelling How lab models built on human biology, from organs-on-chips to AI computer models, can speed drug development and win regulators' acceptance. |
Boehringer Ingelheim Ingelheim am Rhein, Germany | ◆Platinum Sponsor |
Family-owned pharmaceutical company developing human and animal health medicines. | Panel Mon Nov 9 13:00–13:45 Open Innovation in Action: How Pharma Is Rewiring the Drug Discovery Ecosystem How big drug companies share their collections of test molecules and data with outside scientists to speed up early drug discovery. Talk Tue Nov 10 13:00–14:00 Biologics Manufacturing Excellence How makers of biologics, drugs made in living cells, can expand capacity, clear production bottlenecks and use new technology to work more efficiently. Talk Tue Nov 10 09:30–09:45 Pharma Presentation: Boehringer Ingelheim Boehringer Ingelheim, independent since 1885, and its research on human and animal medicines for diseases that lack good treatments. Panel Wed Nov 11 10:00–10:45 Envisioning the future of ophthalmology What new data show about treatments for retinal disease, glaucoma and other eye conditions, and where investors see the most promise. Panel Wed Nov 11 10:00–10:45 Most Favoured Nations: A Game-Changer for Biotech Dealmaker? How the US 'most favoured nation' policy, which ties US drug prices to prices paid abroad, is changing drug deals and European launch plans. |
Informa London, United Kingdom | |
Events, publishing and data group that runs BIO-Europe and publishes BioXconomy. | Keynote Mon Nov 9 10:15–10:30 Talk Mon Nov 9 09:30–10:00 partneringONE essentials workshop Newcomers learn what to expect from partnering meetings, including timing and etiquette, and how to get the most from the partneringONE system. Panel Tue Nov 10 09:00–09:45 Networks or neurons: What’s next in CNS dealmaking? What is driving recent deals between biotechs and larger drug companies for brain and nervous system drugs, which remain hard to develop. Talk Tue Nov 10 11:30–12:00 partneringONE power up workshop Experienced delegates learn advanced partneringONE features and team habits that save time and raise how often their meeting requests are accepted. Panel Wed Nov 11 13:00–13:45 BIO-Europe Media Round-Up: The Stories Shaping Biopharma Right Now Journalists pick out the biggest biopharma news stories and deal trends of the moment and explain what they mean for dealmakers. Panel Wed Nov 11 09:00–09:45 How is the APAC region reshaping global biopharma? How China, Japan, South Korea and other Asia-Pacific countries are moving from making drugs to inventing them, and how Western firms can partner. |
Johnson & Johnson New Brunswick, NJ | ◆Platinum Sponsor · Johnson & Johnson Innovation |
Healthcare company developing innovative medicines and medical technologies; its Innovation unit partners with external researchers and start-ups. | Panel Mon Nov 9 16:15–17:00 Building the Next Global Biotech Hubs: What Makes an Innovation Ecosystem Work? What makes a region a strong biotech hub, from talent, labs and funding to links with global drug companies. Panel Tue Nov 10 10:00–10:25 Regulatory Updates for Orphan and Pediatric Medicines How updated EU drug laws change the rewards for rare-disease and children's medicines, such as longer protection from competing copies. Panel Wed Nov 11 10:00–10:45 Envisioning the future of ophthalmology What new data show about treatments for retinal disease, glaucoma and other eye conditions, and where investors see the most promise. Panel Wed Nov 11 12:00–12:45 What's Next for Biomanufacturing Strategies? Where the manufacturing of biological medicines is heading, from sturdier supply chains and industry mergers to AI and new ways to scale up. |
Novo Nordisk Bagsværd, Denmark | ◆Gold Sponsor |
Danish pharmaceutical company, branded Novo since September 2026, making medicines for diabetes, obesity and rare diseases. | Panel Mon Nov 9 11:15–12:00 Unlocking Pharma’s Productivity Potential Why developing medicines keeps getting costlier and slower, and whether AI and research sourced from other companies can make drug companies more productive. Business of Biotech Panel Tue Nov 10 15:30–15:55 Accelerating Innovation: Creating the Right Environment for Success in Biopharma Partnerships How to design partnerships that work, from payments tied to research milestones and shared risk to guarding intellectual property while sharing ideas. Panel Tue Nov 10 10:00–10:45 Cardiometabolic innovations beyond GLP-1 – Where are we now? Which drug approaches beyond GLP-1 medicines are drawing attention for obesity, diabetes and heart disease risk, and where money and partnerships are going. Panel Tue Nov 10 15:00–15:45 Longevity – Are we getting younger? What recent research shows about treatments that could slow or reverse aging, and how investment in this young field is taking shape. |
Sofinnova Partners Paris, France | |
Life sciences venture capital firm investing from seed to late stage in biotech, medtech and industrial biotech. | Panel Mon Nov 9 16:00–16:45 Cell and Gene Therapy: What Should You Know? Where gene therapies stand across diseases, and what shifting funding and partnerships mean for regulation, manufacturing, investment and market access. Panel Mon Nov 9 16:00–16:45 Fuelling Innovation: The State of Early-Stage Investment in Biotech Investors and founders discuss how young biotech startups raise early funding today and how venture investors' priorities are shifting. Panel Tue Nov 10 15:00–15:45 Scaling Success: The Dynamics of Late-Stage Investment in Biotech How investors back biotechs whose products are close to market, from regulatory hurdles and scaling up to going public or being acquired. |
Eli Lilly Indianapolis, IN | ◇Silver Sponsor |
Global pharmaceutical company with medicines in diabetes, obesity, oncology, immunology and neuroscience. | Keynote Tue Nov 10 13:00–13:45 Keynote: Day in the Life of an experienced dealmaker Experienced drug-company dealmakers and venture investors share how they see the life sciences industry today and how biotechs can find their way. Panel Tue Nov 10 12:20–13:00 Women’s Health at an Inflection Point: Redefining Treatment, Regulatory Pathways and Access How women's health care is changing, from non-hormonal and disease-modifying drugs to new approval and payment routes and new ways of naming diseases. Therapeutic InsightsRegulatory Strategy Panel Tue Nov 10 11:15–12:15 Women’s Health: Healthcare’s Largest Underserved Market and Biggest Growth Opportunity Why women's health is a large, neglected market, and how much value is lost when medicine is designed around the wrong default patient. Therapeutic InsightsBusiness of Biotech |
Ipsen Boulogne-Billancourt, France | ◆Platinum Sponsor |
French global biopharmaceutical company focused on oncology, rare diseases and neuroscience. | Panel Mon Nov 9 13:00–14:00 Navigating partnering and business development in a shifting global landscape How funding conditions, treatment trends and geopolitics are shaping partnerships and acquisitions between drug and biotech companies, with real deal examples. Panel Mon Nov 9 13:00–13:45 The therapeutic landscape backed by analyst insights Which disease areas analysts rate most promising for new drugs and investment, and how new science and rule changes are reshaping them. |
Almirall Barcelona, Spain | ◆Gold Sponsor |
Pharmaceutical company developing and marketing medicines for skin diseases, including psoriasis and atopic dermatitis. | Talk Tue Nov 10 10:00–10:15 Pharma Presentation: Almirall How Almirall, a Barcelona drugmaker focused on skin diseases such as psoriasis and acne, seeks partners from early research to late-stage trials. Panel Wed Nov 11 11:00–11:45 Beyond the surface: The rise and future of dermatology Why skin medicine is drawing investment, from biologics for inflammatory and rare skin diseases to cosmetic treatments, and which deals are emerging. |
Debiopharm Lausanne, Switzerland | ◆Gold Sponsor |
Swiss privately owned biopharmaceutical group developing oncology and bacterial infection treatments. | Panel Mon Nov 9 15:00–15:45 The next oncology winners: Where investors, pharma and biotech are placing their bets Which cancer treatments, from radioactive targeted drugs to newer immunotherapies, now draw investors, and what makes a cancer biotech worth funding. Talk Tue Nov 10 10:15–10:30 Pharma Presentation: Debiopharm International SA How Debiopharm licenses in promising drugs for cancer and bacterial infections, tests them in trials, then picks large drug companies to sell them. |
Find buyers in therapeutic insights
Tell us what you sell and we’ll find the people at organizations working on therapeutic insights most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Browse BIO-Europe 2026 by
Organization type
Track
Everyone
Not affiliated with or endorsed by BIO-Europe or its organizers. Submit a correction